Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 6
1982 47
1983 90
1984 146
1985 265
1986 334
1987 425
1988 495
1989 669
1990 623
1991 667
1992 645
1993 687
1994 643
1995 665
1996 583
1997 647
1998 748
1999 896
2000 1043
2001 1361
2002 1590
2003 1871
2004 2170
2005 2761
2006 3168
2007 3763
2008 4328
2009 5008
2010 5599
2011 6084
2012 6547
2013 6895
2014 7424
2015 7543
2016 7807
2017 8280
2018 8115
2019 3709
2020 69
Text availability
Article attribute
Article type
Publication date

Search Results

92,962 results
Results by year
Filters applied: . Clear all
Page 1
Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology.
Gill C, et al. Curr Neurol Neurosci Rep 2017 - Review. PMID 28819716
RECENT FINDINGS: The number of commercially available, evidence-based therapeutic monoclonal antibodies continues to expand. ...The number of therapeutic monoclonal antibodies encountered in practice continues to grow, as does the number of described neurological complications. ...
RECENT FINDINGS: The number of commercially available, evidence-based therapeutic monoclonal antibodies continues to ex …
CGRP Antibodies as Prophylaxis in Migraine.
Edvinsson L. Cell 2018 - Review. PMID 30550780 Free article.
Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. ...Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. ...
Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvem
A Controlled Trial of Erenumab for Episodic Migraine
Goadsby PJ, et al. N Engl J Med 2017 - Clinical Trial. PMID 29171821 Free article.
BACKGROUND: We tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine. ...CONCLUSIONS: Erenumab administered subcutaneously at a monthly dose of 70 mg or 140 mg significantly reduced migraine frequency, the effects of migraines on daily activities, and the use of acute migraine-specific medication over a period of 6 months. ...
BACKGROUND: We tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the …
Monoclonal Antibodies for Multiple Sclerosis: An Update.
Graf J, et al. BioDrugs 2019 - Review. PMID 30604390
The use of monoclonal antibodies in multiple sclerosis (MS) patients is in a transitional period. Studies regarding well-established, effective antibodies such as natalizumab and alemtuzumab focus more and more on long-term efficacy and safety, risk management, and treating complications. ...While it is very unlikely that monoclonal antibodies will ever cure MS, they have become very valuable therapeutic tools to better patient outcomes. ...
The use of monoclonal antibodies in multiple sclerosis (MS) patients is in a transitional period. Studies regarding wel …
Role of Biologics in Asthma
McGregor MC, et al. Am J Respir Crit Care Med 2019 - Review. PMID 30525902 Free PMC article.
These targeted therapies have been shown to reduce asthma exacerbations, improve lung function, reduce oral corticosteroid use, and improve quality of life in appropriately selected patients. ...This article reviews the mechanism of action, indications, expected benefits, and side effects of each of the currently approved biologics for severe uncontrolled asthma and discusses promising therapeutic targets for the future....
These targeted therapies have been shown to reduce asthma exacerbations, improve lung function, reduce oral corticosteroid use, and i …
Therapeutic monoclonal antibodies.
Breedveld FC. Lancet 2000 - Review. PMID 10703815
The therapeutic potential of monoclonal antibodies (mAb) was quickly realised after the hybridoma technique allowed their development in the mid 1970s. ...The therapeutic use of mAb is now established, and is perhaps the first example of how the "new biology" and the understanding of underlying molecular mechanisms has benefited patients....
The therapeutic potential of monoclonal antibodies (mAb) was quickly realised after the hybridoma technique allowed the …
Fremanezumab for the Preventive Treatment of Chronic Migraine
Silberstein SD, et al. N Engl J Med 2017 - Clinical Trial. PMID 29171818 Free article.
BACKGROUND: Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), is being investigated as a preventive treatment for migraine. ...
BACKGROUND: Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), is being investigated as …
IL-17 inhibitors for psoriasis
Paek SY, et al. Semin Cutan Med Surg 2018 - Review. PMID 30215631
Two monoclonal antibodies targeting IL-17A (secukinumab, ixekizumab) and one antibody against the IL-17 receptor (brodalumab) have been approved for the treatment of moderate-to-severe plaque psoriasis. ...
Two monoclonal antibodies targeting IL-17A (secukinumab, ixekizumab) and one antibody against the IL-17 receptor (brodalumab) …
Fixed Dosing of Monoclonal Antibodies in Oncology.
Hendrikx JJMA, et al. Oncologist 2017 - Review. PMID 28754722 Free PMC article.
Taken together, the minor effects of body size on distribution and elimination of monoclonal antibodies and their usually wide therapeutic window do not support body-size-based dosing. ...For monoclonal antibodies, this results in wide therapeutic windows and no reduced clinical efficacy after fixed dosing. Therefore, we believe that fixed dosing at a well-selected dose can increase medication safety and help in reduction of costs of health care without the loss of efficacy or safety margins....
Taken together, the minor effects of body size on distribution and elimination of monoclonal antibodies and their usually wide …
92,962 results
Jump to page
Feedback